Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Acquisitions & Divestments (2020 - 2022)

Apellis Pharmaceuticals (APLS) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $125.0 million in Q4 2022.

  • For Q4 2022, Change in Acquisitions & Divestments rose 47.04% year-over-year to $125.0 million; the TTM value through Dec 2022 reached $393.3 million, down 6.36%, while the annual FY2022 figure was $393.3 million, 6.36% down from the prior year.
  • Change in Acquisitions & Divestments reached $125.0 million in Q4 2022 per APLS's latest filing, roughly flat from $125.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $312.5 million in Q4 2020 and bottomed at $25.0 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 3 years is $132.8 million, with a median of $125.0 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 72.8% in 2021, then skyrocketed 140.0% in 2022.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $312.5 million in 2020, then plummeted by 72.8% to $85.0 million in 2021, then skyrocketed by 47.04% to $125.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $125.0 million in Q4 2022, $125.0 million in Q3 2022, and $83.3 million in Q2 2022.